Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study-Reference-Cited by-同舟云学术

Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study

Published:2023-06 Issue:6 Volume:23 Page:446-455.e4
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Fu Weijun^ORCID,Bang Soo-Mee,Huang Honghui,Kim Kihyun,Li Wei,An Gang,Lee Je-Jung,Cai Zhen,Jin Jie,Wang Yafei,Lin Tung-Liang,Chim Chor Sang,Qi Ming,Wang Jianping,Lu Xiaolin,Song Yang,Jia Bin,Yang Xue,Liu Wenyu,Zhou Tianyuan,Yin Lu,Li Yunan,Zhang Renyi,Hou Jian^ORCID,Wang Jianxiang^ORCID

Funder

Janssen Research and Development

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. The human CD38 monoclonal antibody daratumumab improves the anti-myeloma effect of lenalidomide with dexamethasone in vitro;de Weers;Blood,2011

2. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

4. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking;Overdijk;J Immunol,2016

5. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

2. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

3. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

4. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16;Blood Advances;2024-07-12

5. Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals;Expert Review of Anticancer Therapy;2024-07-08